Skip to main content

Table 1 Demographics and Clinical characteristics of 173 patients with Behcet’s disease

From: Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet’s disease

Characteristics

BD (n = 173)

ATB (n = 18)

LTB (n = 29)

Previous TB (n = 12)

Non-TB (n = 114)

Age (years, mean ± SD)

37.07 ± 14.74

36.78 ± 10.61

43.52 ± 15.23

42.75 ± 14.06

34.87 ± 14.76

Male (percentage)

114 (65.9%)

11 (61.1%)

23 (79.3%)

5 (41.7%)

75 (65.8%)

BDCAF score (median, range)

2 (0–5)

1.5 (1–5)

2 (0–5)

3 (0–5)

2 (0–5)

Clinical features of BD

 Oral ulcer

170 (98.3%)

18 (100%)

28 (96.6%)

12 (100%)

112 (98.2%)

 Genital ulcer

101 (58.4%)

15 (83.3%)

20 (68.9%)

9 (75%)

57 (50%)

 Skin lesions

101 (58.4%)

13 (72.2%) a

10 (34.5%)

10 (83.3%)

68 (59.6%)

 Erythema nodosa

53 (30.6%)

9 (50%) a

6 (20.6%)

5 (41.6%)

33 (28.9%)

 Pathergy reaction

39 (22.5%)

7 (38.9%)

7 (24.1%)

3 (25%)

22 (19.3%)

Gastrointestinal involvement

68 (39.3%)

5 (27.7%)

12 (41.4%)

5 (41.7%)

46 (40.3%)

 Vascular involvement

49 (28.3%)

7 (38.9%)

9 (31%)

3 (25%)

30 (26.3%)

 Ocular involvement

33 (19%)

4 (22.2%)

3 (10.3%)

1 (8.3%)

25 (21.9%)

 Neurologic involvement

26 (15%)

1 (5.5%)

3 (10.3%)

3 (25%)

19 (16.7%)

Treatment

 Glucocorticoid

113 (65.3%)

12 (66.7%)

22 (75.9%)

6 (50%)

73 (64%)

 Immunosuppressive agents

94 (54.3%)

7 (38.9%)

16 (55.2%)

8 (66.7%)

63 (55.3%)

Biological agents

 Infliximab/Etanercept

12 (6.9%)

2 (11.1%)

2 (6.9%)

1 (8.3%)

7 (6.1%)

  1. ATB compare with LTB; ap<0.05
  2. BD Behçet’s disease, TB tuberculosis, ATB active tuberculosis, LTB latent tuberculosis